Shifts in Massachusetts Biopharma Employment
Biopharma employment in Massachusetts experienced a 3.1% decline throughout 2025, marking a stark end to two decades of consistent year-over-year growth. The state recorded approximately 3,600 fewer jobs compared to 2024 figures. This downturn arrived after a period of near-stagnation, as the industry had previously recorded a meager 0.1% growth rate in 2024. Data from the latest MassBio industry snapshot report indicates that the sector is currently navigating the aftermath of several difficult years.
Kendalle Burlin O’Connell, CEO and President of MassBio, acknowledged the current climate in the report. She described the workforce numbers as indicators of recent industry struggles. Still, some major firms bucked the downward trend. Eli Lilly reported a significant expansion, growing its local presence from 540 to 1,423 employees. Other organizations, including Sanofi, AbbVie, and Alnylam, also added to their local headcounts during this period.
The Divergence Between R&D and Manufacturing
The report reveals a split in performance between research and development roles and biomanufacturing positions. Massachusetts lost 2,563 R&D jobs in 2025, a 3.9% drop that stands as the most significant decrease among major industry hubs. This decline followed a smaller 1.7% contraction in 2024. Despite these losses, the state retains a strong position, as it hosts 22.3% of the total U.S. biopharma R&D workforce.
Biomanufacturing presented a different narrative by posting a 2.4% increase. This gain represents a reversal of the trend observed in 2024, when manufacturing jobs fell by 1.5%. While major hubs in New Jersey and California saw manufacturing job losses, Massachusetts grew its base by 238 positions. Industry analysts point to the state's specialization in high-value advanced-modality manufacturing as a primary driver for this activity, distinguishing it from regions that focus on large-volume production.
Future Outlook and Strategic Priorities
Industry leaders are looking toward systemic changes to stabilize the market. Burlin O’Connell emphasized the necessity for predictable federal funding and a more modernized FDA. A primary strategic focus for the state involves retaining early-stage startups that possess high-risk, high-reward scientific potential. Ensuring these entities have the physical infrastructure and policy support to move from lab findings to clinical data remains a top priority.
The regional ecosystem faces pressure to regain its momentum. Success will depend on the collaborative efforts of government officials, investors, and established pharmaceutical companies. While the data shows a contraction, there is an industry-wide push to restart the engine of innovation. The current goal is to ensure the local workforce can sustain the development of new therapeutic areas for the foreseeable future.